Literature DB >> 33244634

The Benefits of Olanzapine in Palliating Symptoms.

Mellar P Davis1, Gareth J Sanger2.   

Abstract

OPINION STATEMENT: Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the USA. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids are that it may reduce craving, drug cues, and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.

Entities:  

Keywords:  Advanced cancer; Appetite; Nausea; Olanzapine; Substance abuse; Vomiting

Mesh:

Substances:

Year:  2020        PMID: 33244634     DOI: 10.1007/s11864-020-00804-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  139 in total

1.  Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.

Authors:  F P Bymaster; D L Nelson; N W DeLapp; J F Falcone; K Eckols; L L Truex; M M Foreman; V L Lucaites; D O Calligaro
Journal:  Schizophr Res       Date:  1999-05-04       Impact factor: 4.939

2.  Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

Authors:  F P Bymaster; J F Falcone; D Bauzon; J S Kennedy; K Schenck; N W DeLapp; M L Cohen
Journal:  Eur J Pharmacol       Date:  2001-11-02       Impact factor: 4.432

3.  The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.

Authors:  Signe Harder; Jørn Herrstedt; Jesper Isaksen; Mette Asbjoern Neergaard; Karin Frandsen; Jarl Sigaard; Lise Mondrup; Bodil Abild Jespersen; Mogens Groenvold
Journal:  Support Care Cancer       Date:  2019-01-04       Impact factor: 3.603

Review 4.  Definition and classification of cancer cachexia: an international consensus.

Authors:  Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2011-02-04       Impact factor: 41.316

5.  Symptom evaluation in palliative medicine: patient report vs systematic assessment.

Authors:  Jade Homsi; Declan Walsh; Nilo Rivera; Lisa A Rybicki; Kristine A Nelson; Susan B Legrand; Mellar Davis; Michael Naughton; Dragoslav Gvozdjan; Hahn Pham
Journal:  Support Care Cancer       Date:  2006-01-10       Impact factor: 3.603

6.  Insomnia in patients with advanced cancer.

Authors:  Mellar P Davis; Dilara Khoshknabi; Declan Walsh; Ruth Lagman; Alexandra Platt
Journal:  Am J Hosp Palliat Care       Date:  2013-04-23       Impact factor: 2.500

Review 7.  Nausea and Vomiting: a Palliative Care Imperative.

Authors:  Rita J Wickham
Journal:  Curr Oncol Rep       Date:  2020-01-20       Impact factor: 5.075

8.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Authors:  M Shahid; G B Walker; S H Zorn; E H F Wong
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

Review 9.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

10.  Managing Pain in People with Cancer-a Systematic Review of the Attitudes and Knowledge of Professionals, Patients, Caregivers and Public.

Authors:  Salim M Makhlouf; Simon Pini; Shenaz Ahmed; Michael I Bennett
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.